Las Vegas, NV -- (SBWIRE) -- 12/10/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Direxion Shares Exchange Traded Fund Trust(NYSEARCA:NUGT), Genco Shipping & Trading Limited (NYSE:GNK), Hemispherx BioPharma, Inc(NYSEMKT:HEB), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)
Direxion Shares Exchange Traded Fund Trust (NYSEARCA:NUGT) increased 14.41% at the price of $31.37 recently on a traded volume of 961,295.00 shares. So far this year, the stock is down over -42.9%. The company has a total market capitalization of $660.11 million.
For How Long NUGT will Fight for Profitability? Read This Trend Analysis report
Genco Shipping & Trading Limited (NYSE:GNK) plunged -23.89% at the trading price of $1.88 on a traded volume of 4.69 million shares till now, whereas its average trading volume is 1.85 million shares. In the last three months, the stock is down -58.28%. The Intra-day range for the stock is $1.12 and $4.98. Genco Shipping & Trading Limited (GS&T) transports iron ore, coal, grain, steel products and other drybulk cargoes along worldwide shipping routes through the ownership and operation of drybulk carrier vessels. As of December 31, 2012, GS&T’s fleet consisted of 53 drybulk carriers, including nine capesize, eight panama.
Has GNK Found The Bottom And Ready To Gain Momentum? Find Out Here
Hemispherx BioPharma, Inc(NYSEMKT:HEB) dropped down -11.65% at the $0.278 recently. So far in three months, the stock is up 13.31%. The 52-week range for the stock is $0.18 and $0.75. Its introductory price for the day was $0.33, with the overall traded volume of 4.32 million shares. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Why Should Investors Buy HEB After the Recent Fall? Just Go Here and Find Out
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), after opening its shares at the price of $2.08, jumped up13.66% , its recent trading price was $2.08 for the day. The stock moved on a traded volume of 4.36 million shares, in comparison to 1.52 million shares of average trading volume. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents.
Why Should Investors Buy NAVB After The Recent Gain? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)